Recent Company News

• 06:38 AM ET Apr 18, 2026
  

  argenx to present new data for VYVGART at AAN Annual Meeting ($849.04, 0.00)

• 09:34 AM ET Apr 09, 2026
  

  Follow-up: Forte Biosciences discloses Argenx BV has made a strategic investment in the company as part of its 5.7M secondary offering - 8-K ($29.95, +3.68)

• 07:46 AM ET Apr 01, 2026
  

  Goldman Sachs monthly changes to European Conviction List - Directors' Cut (pre-European open)

• 09:47 AM ET Mar 23, 2026
  

  StreetAccount Summary - Private company transactions for the week ended 21-Mar

• 12:10 PM ET Mar 18, 2026
  

  StreetAccount Summary - U.S. Unusual Option Volume: VIX +3.3% to $23.10; S&P 500 (0.6%) to $6,678.99

• 03:58 AM ET Mar 11, 2026
  

  StreetAccount Summary - European pre-market trading update

• 03:29 PM ET Mar 10, 2026
  

  argenx upgraded to buy from hold at Deutsche Bank ($744.74, +4.34)

• 01:04 AM ET Mar 06, 2026
  

  argenx to present new data at AAN Annual Meeting ($728.11, 0.00)

• 12:31 PM ET Mar 02, 2026
  

  Transcript Intelligence: argenx at TD Cowen Health Care Conference ($757.58, -9.34)

• 05:27 PM ET Feb 26, 2026
  

  StreetAccount Sector Summary - Healthcare Post-Market